Note: data can be out of date. fill free contact with us for more information.
|body||Copenhagen, 15 July 2016 – Zealand informs that the company has received a major shareholder announcement from Sunstone LSV Management A/S, Lautrupsgade 7, 5., 2100 Copenhagen (CVR no. 33 85 91 98). The major shareholder announcement follows a previous released announcement from Zealand (company announcement no. 22 from 2 June 2016) with information regarding a planned voluntary liquidation of four funds, all being managed by Sunstone LSV Management A/S, which expectedly during Q3 2016 would lead to the distribution of a part of the share capital in Zealand to a broader group of institutional investors. Pursuant to Section 29 of the Danish Securities Trading Act, cf. Executive order no. 1256 of 4 November 2015 on Major Shareholders and Section 55, cf. Section 56 of the Danish Companies Act, Zealand has been informed that the four funds: P/S Sunstone Biomedicinsk Venture III K/S Sunstone Biomedical Ventures Annex I K/S Sunstone Biomedical Ventures Annex II K/S Sunstone Biomedical Ventures Annex III in relations to their liquidation all shares held by the funds in Zealand will be distributed to the funds’ underlying investors as of today. As previously announced, no investor will receive more than 5% of the share capital in Zealand. Following the liquidation of the above mentioned four funds and the distribution of shares, Sunstone LSV Management A/S will manage and may exercise voting rights on 2,083,483 shares, corresponding to 8.49% of the total voting rights in Zealand Pharma A/S, on behalf of Sunstone Life Science Ventures Fund I K/S.|
The Blueshirt Group
|body||TYSONS, Va., July 15, 2016 (GLOBE NEWSWIRE) -- Alarm.com Holdings, Inc. (Nasdaq:ALRM), the leading platform solution for the connected home and business, today announced that it will report 2016 second quarter financial results after the market close on August 15, 2016. Management will host a conference call and webcast to discuss the Company's financial results at 5:00 p.m. ET that same day.
What: Alarm.com 2016 Second Quarter Financial Results Conference Call When: August 15, 2016 Time: 5:00 p.m. ET Live Call: US/Canada Toll-Free: (877) 445-1593
International: (267) 753-2138 Replay: US/Canada Toll-Free: (855) 859-2056
International: (404) 537-3406
Conference ID: 50535738
(Available approximately two hours after the completion of the live call until 11:59 p.m. ET on August 22, 2016) Webcast: http://investors.alarm.com/ About Alarm.com Holdings, Inc. Alarm.com is the leading platform solution for the connected home and business. Millions of people depend on Alarm.com's technology to monitor and control their property from anywhere. Centered on security and remote monitoring, our platform addresses a wide range of market needs and enables application-based control for a growing variety of Internet of Things (IoT) devices. Our security, video monitoring, intelligent automation and energy management solutions are available through our network of thousands of professional service providers in North America and around the globe. Alarm.com's common stock is traded on the Nasdaq under the ticker symbol ALRM. For more information, please visit www.alarm.com. CONTACT:
The Blueshirt Group
|contact_data||Media / Investor Relations Contact:
Charles E. Schneider
SVP & Chief Financial Officer
Tel: +1 (281) 674-0699|
|body||HOUSTON, July 15, 2016 (GLOBE NEWSWIRE) -- RigNet, Inc. (NASDAQ:RNET), a leading global provider of digital technology solutions, today announced a corporate restructuring plan to create more common processes and more consistent customer experiences across our global footprint. The plan creates a single global managed services sales organization to drive both market share and revenue growth. Through this restructuring, RigNet has created dedicated teams to drive entry into new vertical markets and to deliver additional over-the-top applications to both existing and new managed services customers.
The effects of the restructuring include a flattening of the organization, a streamlining of decision making and, as a result, a more efficient business model. In connection with this action, RigNet expects to achieve annualized savings from personnel, facility and other reductions of approximately $3.5 million after taking a restructuring charge of approximately $4.5 million in the third quarter of 2016 for employee severance expenses, facilities costs and related matters. Expected to be substantially completed by December 31, 2016, the plan involves a reduction across the organization of approximately 12% of the employee base. By implementing this new organizational structure, the company will reduce spending and both flatten and streamline the organization to provide best-in-class customer experiences across the world. We will be better positioned to generate revenues from over-the-top applications that can help our customers drive efficiency in their businesses. And, through more focused efforts, we will be better positioned to grow revenue in new vertical markets," said Steven Pickett, RigNet's CEO and president. "We believe that this action creates the right structure and a properly sized organization to better position us for the future.” About RigNet RigNet (NASDAQ:RNET) is a leading global provider of digital technology solutions focusing on serving energy facilities, maritime vessels and other global remote locations. RigNet provides solutions ranging from fully-managed voice and data networks to more advanced applications that include video conferencing and real-time data services to more than 1,000 remote sites in over 50 countries on six continents. RigNet is based in Houston, Texas. For more information on RigNet, please visit www.rig.net. RigNet is a registered trademark of RigNet, Inc. Media / Investor Relations Contact:|
|id||Charles E. Schneider |
|id||SVP & Chief Financial Officer|
|id||RigNet, Inc. |
|id||Tel: +1 (281) 674-0699"|
Hutchinson Technology Inc.
Hutchinson Technology Inc.
|body||HUTCHINSON, Minn., July 15, 2016 (GLOBE NEWSWIRE) -- Hutchinson Technology Incorporated (NASDAQ:HTCH) today announced it will report fiscal 2016 third quarter financial results on Friday, July 29, 2016, before the open of the market. No conference call will be held.
About Hutchinson Technology
Hutchinson Technology is a global supplier of critical precision component technologies. As a key supplier of suspension assemblies for disk drives, we help customers improve overall disk drive performance and meet the demands of an ever-expanding digital universe. Through our new business development initiatives, we focus on leveraging our unique precision manufacturing capabilities in new markets to improve product performance, reduce size, lower cost, and reduce time to market. INVESTOR CONTACT:
Hutchinson Technology Inc.
Hutchinson Technology Inc.
William R. Gargiulo, Jr.
Michele Greco, CFO
|body||CHICAGO, July 15, 2016 (GLOBE NEWSWIRE) -- The Female Health Company (FHC or the Company) (NASDAQ:FHCO), manufacturer of the world’s leading female condom, the FC2, today announced that July 28, 2016 is the record date for the Company’s special meeting of shareholders to be held in connection with the previously announced proposed merger transaction between FHC and Aspen Park Pharmaceuticals, Inc. (APP). The date, time and location of the special meeting will be set and announced at a later time. Only holders of record of the Company’s common stock at the close of business on July 28, 2016 will be entitled to notice of the special meeting and to vote and have their votes counted at the special meeting and any adjournments or postponements of the special meeting.
As previously announced, FHC entered into a definitive merger agreement with APP. FHC believes that the proposed transaction with APP provides an extraordinary opportunity to establish a new company with the potential to enhance both short-term and long-term stockholder value. The new company will have multiple products that provide opportunities for growth, while mitigating the risk associated with FHC being a single product company. The new company will have five proprietary pharmaceutical product opportunities. Three of the proprietary product opportunities are candidates for the FDA 505(b)(2) regulatory pathway. The 505(b)(2) pathway permits the use of established data on currently marketed products for securing new claims and/or dosage forms for such products. This may reduce the time required, cost and risk in developing and securing FDA approval. The new company will include a women’s health division, that will focus on expanding FHC’s existing, profitable business, while beginning development of newly acquired oncology assets for breast and ovarian cancer, and a men’s health division, focused on the areas of benign prostatic hyperplasia, male infertility, hot flashes in men on prostate cancer therapy, gout and advanced prostate cancer, together with consumer health products for premature ejaculation and sexual health vitamin supplements. Following the business combination, the Company will be renamed Veru Healthcare Inc. FHC has filed a preliminary proxy statement with the Securities and Exchange Commission (SEC) relating to the special meeting which is being reviewed by the SEC. The full meeting agenda will be detailed in FHC's definitive proxy statement, which will be mailed to all stockholders of record as of the record date after it has been filed with the Securities and Exchange Commission (SEC) following the completion of the review of the preliminary proxy statement. For those parties interested in learning more about the proposed merger transaction between The Female Health Company and Aspen Park Pharmaceuticals, please visit: www.femalehealth.com/investors/merger-documents. About Aspen Park Pharmaceuticals Aspen Park Pharmaceuticals, Inc. is a privately held therapeutics company focused on the development and commercialization of pharmaceutical and consumer health products for men’s and women’s health and oncology. For men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, gout, sexual dysfunction, and prostate cancer. For women, product candidates are for advanced breast and ovarian cancers and for female sexual health. Aspen Park Pharmaceuticals is planning to launch in the United States the PREBOOST™ OTC product for treating premature ejaculation in Q4 of fiscal 2016. Aspen Park Pharmaceuticals has offices in New York City, New York. For more information on PREBOOST™ OTC product visit www.preboost.com or for more information on APP visit www.aspenparkpharma.com. About The Female Health Company The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2). Since the Company began distributing FC2 in 2007, the product has been shipped to 144 countries. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in a number of countries around the world. The patents cover key aspects of FC2, including its overall design and manufacturing process. The FC2 Female Condom® is the only currently available female-controlled product approved by FDA that offers dual protection against sexually transmitted infections, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies. Forward-Looking Statements This press release contains forward-looking statements, including those regarding the proposed merger transaction between FHC and APP and the integration of our two businesses. These statements are subject to known and unknown risks, uncertainties and assumptions, and if any such risks or uncertainties materialize or if any of the assumptions prove incorrect, our actual results could differ materially from those expressed or implied by such statements. These risks and uncertainties include but are not limited to: the risk that the proposed transaction may not be completed in a timely manner or at all; the satisfaction of conditions to completing the transaction, including the ability to secure approval by a two-thirds vote of FHC’s shareholders; risks that the proposed transaction could disrupt current plans and operations; costs, fees and expenses related to the proposed transaction; risks related to the development of APP's product portfolio, including regulatory approvals and time and cost to bring to market; risks relating to the ability of the combined company to obtain sufficient financing on acceptable terms when needed to fund development and company operations; the risk that, even if it is completed, we may not realize the expected benefits from the transaction; and other risks described in FHC’s filings with the SEC, including our Annual Report on Form 10-K for the year ended September 30, 2015 and our Quarterly Reports on Form 10‑Q for the quarters ended December 31, 2015 and March 31, 2016. These documents are available on the SEC Filings" section of our website at http://fhcinvestor.com. All forward-looking statements are based on information available to us as of the date hereof, and FHC does not assume any obligation and does not intend to update any forward-looking statements, except as required by law. Additional Information about the Proposed Transaction and Where You Can Find It FHC plans to file a definitive proxy statement with the SEC relating to a solicitation of proxies from its shareholders in connection with a special meeting of shareholders of FHC to be held for the purpose of voting on matters relating to the proposed transaction. BEFORE MAKING ANY VOTING DECISION WITH RESPECT TO THE PROPOSED TRANSACTION, FHC SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND OTHER RELEVANT MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. The proxy statement and other relevant materials, and any other documents filed by FHC with the SEC, may be obtained free of charge at the SEC's website at www.sec.gov. In addition, shareholders of FHC may obtain free copies of the documents filed with the SEC by contacting FHC's Chief Financial Officer at (312) 595-9123, or by writing to Chief Financial Officer, The Female Health Company, 515 North State Street, Suite 2225, Chicago, Illinois 60654. Interests of Certain Participants in the Solicitation FHC and its executive officers and directors may be deemed to be participants in the solicitation of proxies from the shareholders of FHC in favor of the proposed transaction. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement and other relevant materials to be filed with the SEC when they become available. For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com. Contacts:|
|id||William R. Gargiulo, Jr.|
|id||Michele Greco, CFO|
Zhao Lichao IR Director
Tel: 86-183 2119 5582
|body||BEIJING, July 15, 2016 (GLOBE NEWSWIRE) -- Wowo Limited (the “Company” or “JM Wowo”) (NASDAQ:JMU), a leading B2B online e-commerce platform that provides integrated services to suppliers and customers in the foodservice industry in China, today announced that the Shanghai Zhongmin Supply Chain Management Co., Ltd., JM Wowo’s consolidated affiliated entity in China, is among the first group of 94 Shanghai-based trading companies that received the ‘Regional Headquarters Certificate’ from the Shanghai government, recognizing it as one of the key trading companies headquartered in Shanghai.
The 94 domestic and foreign companies are engaged in wholesale and retail, international trading, logistics and warehouse, and e-commerce platform operations. For e-commerce companies, certificates were only granted to those with more than RMB15 billion (US $2.3 billion) in annual merchants’ gross merchandise volume and 5,000 registered merchants, at least 30% of which are non-local merchants. As a leading B2B platform in China’s catering industry, JM Wowo now has over 10,000 third-party sellers on the Company’s online marketplace and over 28,000 active customer accounts as of March 31, 2016. Ms. Xiaoxia Zhu, Co-chairperson and Chief Executive Officer commented, “We are honored to be among the first group of trading companies that received the ‘Regional Headquarters Certificate’, which represents the efforts by the local government to build Shanghai into an international trading center. The certificate is an important way to expand our influence as a key enterprise supported by the Shanghai government. We believe this is a testament to the strong reputation and strength of our foodservice B2B platform expertise. By utilizing our experience and expertise in both the online and traditional industries, we have confidence that our online marketplace will attract more merchants and create long-term value for our customers and shareholders.” About JM Wowo Limited Wowo Limited currently operates China’s leading B2B online e-commerce platform that provides integrated services to suppliers and customers in the foodservice industry. With the help of Internet and cloud technologies, the Company has the vision to reshape the procurement and distribution pattern and build a fair business ecosystem in the catering industry in China. The Company is further promoting the use of its platform for small- and medium-sized restaurants and restaurant chains in China. Through cooperation with national and local industry associations and reputable restaurant groups across China, the Company has formed a leading industrial alliance and has great resource leverage in China’s catering industry. The Company works closely with suppliers and customers in the catering industry, providing one-stop procurement services, as well as other value-added services. Safe Harbor Statement This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “aim”, “anticipate”, “believe”, “estimate”, “expect”, “going forward”, “intend”, “ought to”, “plan”, “project”, “potential”, “seek”, “may”, “might”, “can”, “could”, “will”, “would”, “shall”, “should”, “is likely to” and the negative form of these words and other similar expressions. Among other things, statements that are not historical facts, including statements about the Company’s beliefs and expectations, the business outlook and quotations from management in this announcement, as well as the Company’s strategic and operational plans, are or contain forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: The general economic and business conditions in China may deteriorate. The growth of Internet and mobile user population in China might not be as strong as expected. The Company’s plan to enhance customer experience, upgrade infrastructure and increase service offerings might not be well received. The Company might not be able to implement all of its strategic plans as expected. Competition in China may intensify further. All information provided in this press release is as of the date of this press release and are based on assumptions that we believe to be reasonable as of this date, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law. Contact:
Zhao Lichao IR Director
Tel: 86-183 2119 5582
|body||HENDERSON, Nev., July 15, 2016 (GLOBE NEWSWIRE) -- Oroplata Resources, Inc. (“Oroplata” or the “Company”) (OTCBB:ORRP) is pleased to provide the following update on the Company’s activities. The Oroplata geological team is in the process of reviewing all available well data and refining a planned 2016 Exploration Program of drilling and geophysics for the Western Nevada Basin (WNB) lithium project.
The WNB Project is located approximately 94 miles (151 kilometers) northeast of Tonopah, NV, in Nye County, Nevada. Oroplata holds a 100% interest in 500 claims over 10,000 acres in one of Nevada’s largest trapped drainage basins in an area that was first identified as lithium rich by the United States Geological Survey (USGS). The Company also has an exclusive option to acquire an additional 700 mining claims in the area for a total of 24,000 acres. Oroplata believes the WNB project has the potential to host lithium-bearing brines in subterranean aquifers beneath the valley floor. Historical oil exploration and development data obtained by Oroplata indicate that geologic formations and brines are present that appear to be very similar to the lithium brine deposit model of the Clayton Valley. Clayton Valley hosts the Silver Peak lithium brine mine, which is operated by Albemarle Corp. Lithium brine projects are known to be lower cost to explore and develop compared to hard rock mining alternatives; they are quicker in proving up a resource and reserves; they are faster and much less capital intensive to put into production. The WNB project is located within Railroad Valley, a valley that is over 100 miles long and 15 to 25 miles wide that drains a 3,000+ square mile area. Sampling of dry sediment in the basin has found lithium values ranging from 50 to 247 ppm. The higher lithium values were concentrated almost entirely over a 40-mile by 16-mile section that contains the WNB project. The current claim configuration also covers a massive gravity low feature. Oroplata’s planned drilling program will be optimized both in technology and locations so as best to test the brine horizons and examine the overall reservoir potential of the basin. Surficial and downhole geophysics will be employed to help generate a better understanding of the lateral extent of the brine horizons. The program will also be specifically designed to rapidly produce a resource and advance economic analysis by testing brine flow rates. Additional details relating to the drilling program will be released prior to the initiation of drilling. Craig Alford, Oroplata’s CEO stated, “We are very excited to be readying ourselves for a drilling and geophysics program at the high-potential WNB lithium project in Nevada. Going forward, we will continue to take our responsibilities as an emerging publicly traded company very seriously. As such, in order to facilitate the timely and accurate release of information to our valued shareholders and the investment community, Oroplata will maintain its policy to disseminate corporate material exclusively through its website, filings with the SEC, and through Company issued press releases only. These channels offer the most efficient and transparent way to distribute our corporate message and provide all market participants with the most factual and up-to-date information publicly available. We caution readers that information and opinions of third party commentators are not issued by the Company, may contain inaccuracies or out-of-date information, and should not be solely relied upon when making investment decisions. Oroplata encourages all interested parties to review information and press releases available at its website and SEC.gov.” About Oroplata: Oroplata Resources Inc. is focused on becoming a substantial profitable lithium producer by the rapid development of valuable production-grade lithium brine deposits in Nevada and throughout the southwest United States. For more information about Oroplata Resources, visit: www.oroplataresourcesinc.com. IR Contact: Kingston Advisors +1-212-796-5290 firstname.lastname@example.org www.kingstonadvisors.com Safe Harbor Statements Certain information contained in this news release constitutes “forward-looking statements” as such term is used in applicable United States and Canadian laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “expects” or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “estimates”, “intends” or “believes”, or that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur”, or “be achieved”. Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the SEC. Such risks and other factors include, among others, the ability to locate and acquire suitable interests in alternative medicine manufacturing operations on terms acceptable to the Company, the availability of financing on acceptable terms, accidents, labor disputes, acts of God and other risks of the alternative medicine industry including, without limitation, delays in obtaining governmental approvals or permits, title disputes or claims limitations on insurance coverage. The Company believes that the expectations reflected in the forward-looking statements included in this news release are reasonable; however, no assurance can be given that these expectations will prove to be correct, and such forward-looking statements should not be unduly relied upon. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.|
|contact_data||Contact in US:
|body||WATERTOWN, Mass., July 15, 2016 (GLOBE NEWSWIRE) -- pSivida Corp (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced today that it is implementing a site consolidation plan in support of its product development program and plans to conduct all future research and product development in a single location. Subject to an employee consultation process required by local U.K. law, pSivida proposes to close its research facility in Malvern, U.K. and locate all research and product development activities in the Company’s state-of-the-art, cGMP facility in Watertown, MA.
Dr. Paul Ashton, president and CEO of pSivida, said, “We look forward to the seamless consolidation of the Durasert™ and Tethadur™ research and development work being done in our U.K. and our U.S. facilities in a single location. We believe this restructuring will focus our R&D efforts and facilitate product development while reducing operating expenses.” pSivida expects the site consolidation plan will reduce pre-tax operating expenses by approximately $900,000 annually, beginning in the second quarter of fiscal year 2017, ending December 31, 2016. pSivida estimates that it will record approximately $680,000 of charges associated with the plan, of which approximately $550,000 is estimated to be cash expenditures. Actual charges may vary due to various factors, including currency exchange ratios and the outcome of the consultation process. The charges are expected to be recorded primarily in the first quarter of fiscal 2017, ending September 30, 2016, with the site consolidation expected to be substantially completed during that quarter, subject to local U.K. labor requirements. About pSivida Corp. pSivida Corp. (www.psivida.com), headquartered in Watertown, MA, is a leader in the development of sustained release, drug delivery products for treating eye diseases. pSivida has developed three of only four FDA-approved sustained-release treatments for back-of-the-eye diseases. The most recent, ILUVIEN®, a micro-insert for diabetic macular edema, licensed to Alimera Sciences, is currently sold in the U.S. and three EU countries. Retisert®, an implant for posterior uveitis, is licensed to and sold by Bausch & Lomb. pSivida’s lead product candidate, Medidur™, a micro-insert for posterior uveitis being independently developed, is currently in pivotal Phase 3 clinical trials, with an NDA anticipated in 2017. pSivida’s pre-clinical development program is focused on using its core platform technologies Durasert™ and Tethadur™ to deliver drugs and biologics to treat wet and dry age-related macular degeneration, glaucoma, osteoarthritis and other diseases. To learn more about pSivida please visit www.psivida.com and connect on Twitter, LinkedIn, Facebook and Google+. SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements include uncertainties with respect to: actual amounts incurred to implement the site consolidation and actual savings achieved as a result; the safety and efficacy of the TKI insert for wet AMD, the initiation and completion of clinical trials and potential marketing approval of the insert; designation of Medidur as an orphan medicinal product; our ability to achieve profitable operations and access to capital; fluctuations in our operating results; further impairment of our intangible assets; declines in Retisert royalties; successful commercialization of, and receipt of revenues from, ILUVIEN for DME; the effect of pricing and reimbursement decisions on sales of ILUVIEN for DME; consequences of fluocinolone acetonide side effects; safety and efficacy results of the second Medidur Phase 3 trial, number of trials and data required for, and timing of filing and acceptance of, the Medidur NDA and EU marketing approval applications, if at all; ability to use data in a U.S. NDA from trials outside the U.S.; any exercise by Pfizer of its option with respect to the latanoprost product; our ability to develop Tethadur to successfully deliver large biologic molecules and develop products using it; our ability to successfully develop product candidates, initiate and complete clinical trials and receive regulatory approvals; our ability to market and sell products; the success of current and future license agreements; termination or breach of current license agreements; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; legislative or regulatory changes; volatility of stock price; possible dilution; absence of dividends; and other factors described in our filings with the SEC. You should read and interpret any forward-looking statements in light of these risks. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements, even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized. Contact in US:
|body||_wige MEDIA AG
Dissemination of a Voting Rights Announcement, transmitted by
DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Notification of Major Holdings
1. Details of issuer
_wige MEDIA AG
Am Coloneum 2
2. Reason for notification
Acquisition/disposal of shares with voting rights
Acquisition/disposal of instruments
Change of breakdown of voting rights
X Other reason:
Holding notice according to §41.4 g
FiMaNoG (Amendment to the German financial market law)
3. Details of person subject to the notification obligation
Name: City and country of registered
Versorgungswerk der Zahnärztekammer 40547 Duesseldorf Germany
4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
Sondervermögen UZN - Universal - Fonds
5. Date on which threshold was crossed or reached
26 Apr 2016
6. Total positions
% of voting % of voting rights total of total number
rights attached through instruments both in % of voting
to shares (total (total of 7.b.1 + (7.a. + rights of
of 7.a.) 7.b.2) 7.b.) issuer
Result- 4.14 % 0 % 4.14 % 14,726,329
Previo- % % % /
7. Notified details of the resulting situation
a. Voting rights attached to shares (Sec.s 21, 22 WpHG)
ISIN absolute in %
direct indirect direct indirect
(Sec. 21 WpHG) (Sec. 22 WpHG) (Sec. 21 WpHG) (Sec. 22 WpHG)
DE000A1EMG56 610,000 % 4.14 %
Total 610,000 4.14 %
b.1. Instruments according to Sec. 25 para. 1 No. 1 WpHG
Type of Expiration or Exercise or Voting Voting
instrument maturity date conversion rights rights in
period absolute %
b.2. Instruments according to Sec. 25 para. 1 No. 2 WpHG
Type of Expiration Exercise or Cash or Voting Voting
instrume- or maturity conversion physical rights rights
nt date period settlement absolute in %
8. Information in relation to the person subject to the notification
X Person subject to the notification obligation is not controlled and
does itself not control any other undertaking(s) holding directly
or indirectly an interest in the (underlying) issuer (1.).
Full chain of controlled undertakings starting with the ultimate
controlling natural person or legal entity:
Name % of voting rights % of voting rights Total of both (if
(if at least held 3% through instruments (if at least held 5%
or more) at least held 5% or more) or more)
9. In case of proxy voting according to Sec. 22 para. 3 WpHG
Date of general meeting:
Holding position after general meeting: % (equals voting rights)
10. Other explanatory remarks:
14.07.2016 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Company: _wige MEDIA AG
Am Coloneum 2
End of Announcement DGAP News-Service
|body||ALMERE, The Netherlands, July 15, 2016 (GLOBE NEWSWIRE) -- ASM International N.V. (Euronext Amsterdam: ASM) will report operating results for the 2016 second quarter ended June 30, 2016 at approximately: 18:00 p.m. Continental European Time - Thursday, July 28, 2016 12:00 a.m. (noon) US Eastern Time - Thursday, July 28, 2016. ASM International will host an investor conference call and web cast on Friday, July 29, 2016 at 15:00 Continental European Time (9:00 a.m. - US Eastern Time). The teleconference dial-in numbers are as follows: United States: +1 646 254 3363 International: +44 (0)20 3427 1919 The Netherlands: +31 (0)20 716 8296 Access Code: 485540 A simultaneous audio webcast and replay will be accessible at www.asm.com. About ASM International ASM International NV, headquartered in Almere, the Netherlands, its subsidiaries and participations design and manufacture equipment and materials used to produce semiconductor devices. ASM International, its subsidiaries and participations provide production solutions for wafer processing (Front-end segment) as well as for assembly & packaging and surface mount technology (Back-end segment) through facilities in the United States, Europe, Japan and Asia. ASM International's common stock trades on the Euronext Amsterdam Stock Exchange (symbol ASM). For more information, visit ASMI's website at www.asm.com. Cautionary Note Regarding Forward-Looking Statements: All matters discussed in this press release, except for any historical data, are forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These include, but are not limited to, economic conditions and trends in the semiconductor industry generally and the timing of the industry cycles specifically, currency fluctuations, corporate transactions, financing and liquidity matters, the success of restructurings, the timing of significant orders, market acceptance of new products, competitive factors, litigation involving intellectual property, shareholders or other issues, commercial and economic disruption due to natural disasters, terrorist activity, armed conflict or political instability, epidemics and other risks indicated in the Company's reports and financial statements. The Company assumes no obligation nor intends to update or revise any forward-looking statements to reflect future developments or circumstances. CONTACT Investor contact: Victor Bareño
T: +31 88 100 8500
E: email@example.com Media contact: Ian Bickerton
T: +31 625 018 512 ASMI announces availability and timing of Q2 2016 call and webcast http://hugin.info/132090/R/2028873/754279.pdf HUG#2028873|
|body||Nasdaq Stockholm decides to officially list 3 bond loans issued by Skandinaviska Enskilda Banken AB with effect from 2016-07-18. The instruments will be listed on STO Structured Products.
Please find instrument identifiers in the attached document.
Nasdaq Stockholm AB, Issuer Surveillance, firstname.lastname@example.org, +46 8 405 7050|
|body||Landesbank Hessen-Thüringen Girozentrale / Preliminary announcement on the
disclosure of financial statements
Preliminary announcement of the publication of financial reports according to
Articles 37v, 37w, 37y of the WpHG [the German Securities Act], transmitted by
DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Landesbank Hessen-Thüringen Girozentrale hereby announces that the
financial reports shall be disclosed :
Report: Financial report of the group (half-year/Q2)
Date of disclosure / German: August 31, 2016
Date of disclosure / English: August 31, 2016
15.07.2016 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Company: Landesbank Hessen-Thüringen Girozentrale
Neue Mainzer Str. 52-58
60311 Frankfurt am Main
End of Announcement DGAP News-Service
Chief Financial Officer
|body||WINTER SPRINGS, Fla., July 15, 2016 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2016 second quarter financial results before the market opens on Friday, July 29th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.
Individuals interested in listening to the conference call may do so by dialing 1-844-413-1781 for domestic callers, or 1-716-247-5767 for international callers, and entering reservation code 50949035. The conference call will also be available real-time via the Internet at www.iradimed.com/en-us/investors/index.php and selecting Events & Presentations. A recording of the call will be available on the Company’s website for 90 days following completion of the call. About IRADIMED CORPORATION IRADIMED CORPORATION is the only known provider of non-magnetic intravenous (IV) infusion pump systems that are specifically designed to be safe for use during magnetic resonance imaging (MRI) procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency (RF) interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, uniquely-designed non-ferrous parts and other special features in order to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically-ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated in order to remain immobile during an MRI scan. Media Contact:
Chief Financial Officer
North America: Jon Luebke, Syntel, 248/619-3503, email@example.com
Europe and International: Rani Gill, Flame PR, +44 0203 357 9746, Syntel@flamepr.com|
|body||TROY, Mich., July 15, 2016 (GLOBE NEWSWIRE) -- Syntel, Inc. (Nasdaq:SYNT), a global provider of digital transformation, information technology and knowledge process services to Global 2000 companies, will announce results for the Second Quarter 2016, before the market opens on Thursday, July 21, 2016.
Syntel management will conduct a conference call at 10:00 a.m. (EDT) to discuss financial and operating performance for the quarter. To participate in the conference call, participants in the U.S./Canada should dial (877) 837-3915. International callers should dial (973) 638-3495. The conference call will also be available live via the Internet by accessing the Syntel web site at investor.syntelinc.com. Please access the site at least fifteen minutes prior to the call to register, download and install any necessary software. For those who cannot access the live broadcast, a replay will be available until July 28, 2016 by dialing (855) 859-2056 and entering 48344679". International callers may dial (404) 537-3406 and enter the same passcode. About Syntel Syntel (Nasdaq:SYNT) is the global leader in digital modernization services, with a core suite of automation-driven IT and knowledge process services. Syntel helps global enterprises thrive in the Two-Speed World™ by building agile, efficient technology infrastructures that blend legacy business models with disruptive digital innovations. Syntel’s recursive automation platform, SyntBots®, enables clients to manage, migrate, and modernize their business and technology ecosystems. Syntel believes in a "Customer for Life" philosophy to build collaborative partnerships and creates long-term business value for its clients by investing in IP, solutions and industry-focused delivery teams with deep domain knowledge. To learn more, visit us at www.syntelinc.com. Safe Harbor Provision This news release may include forward-looking statements, including those with respect to the future level of business for Syntel, Inc. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements as a result of certain risk factors set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 or from other factors not currently anticipated. Contacts:|
|id||North America: Jon Luebke, Syntel, 248/619-3503, firstname.lastname@example.org|
|id||Europe and International: Rani Gill, Flame PR, +44 0203 357 9746, Syntel@flamepr.com"|
InterCloud Systems, Inc.
|body||SHREWSBURY, N.J., July 15, 2016 (GLOBE NEWSWIRE) -- InterCloud Systems, Inc. (Nasdaq:ICLD) a leading provider of cloud networking orchestration, automation solutions, and services, announced today that it recently completed over $3.8 Million in professional service deployments supporting a tier 1 service provider’s network maintenance and installations in the Northeastern portion of the United States.
Mark Munro, CEO of InterCloud Systems stated: While we build upon our backlog of significant new business we were recently opportunistic in taking on a significant amount of new projects to assist a carrier that needed our immediate help to support its customers. This work was started and completed during the second quarter 2016.” About InterCloud Systems, Inc. InterCloud Systems, Inc. is a leading provider of cloud networking orchestration and automation, for Software Defined Networking (SDN) and Network Function Virtualization (NFV) cloud environments to the telecommunications service provider (carrier) and corporate enterprise markets through cloud solutions and professional services. InterCloud's cloud solutions offer enterprise and service-provider customers the opportunity to adopt an operational expense model by outsourcing cloud deployment and management to InterCloud rather than the capital expense model that has dominated in recent decades in IT infrastructure management. Additional information regarding InterCloud may be found on InterCloud's website at www.intercloudsys.com. Forward-looking statements: The above news release contains forward-looking statements. The statements contained in this document that are not statements of historical fact, including but not limited to, statements identified by the use of terms such as "anticipate," "appear," "believe," "could," "estimate," "expect," "hope," "indicate," "intend," "likely," "may," "might," "plan," "potential," "project," "seek," "should," "will," "would," and other variations or negative expressions of these terms, including statements related to expected market trends and the Company's performance, are all "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve a number of risks and uncertainties. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performances, and are subject to a wide range of external factors, uncertainties, business risks, and other risks identified in filings made by the company with the Securities and Exchange Commission. Actual results may differ materially from those indicated by such forward-looking statements. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based except as required by applicable law and regulations. CONTACT:|
|id||InterCloud Systems, Inc.|
|body||Nasdaq Stockholm decides to officially list 1 bond loan issued by Skandinaviska Enskilda Banken AB with effect from 2016-07-18. The instrument will be listed on STO Structured Products.
Please find instrument identifiers in the attached document.
Nasdaq Stockholm AB, Issuer Surveillance, email@example.com, +46 8 405 7050|
|body||Comptel Corporation, Stock Exchange Release 15 July 2016 at 3 PM EET Comptel announces preliminary information about the second quarter and the first half of 2016. Key figures for the second quarter of 2016: · Net sales EUR 25.3 million (April - June 2015: 21.7), growth 16.3% · Operating result EUR 3.0 million (0.6), growth 428.5% · Operating result of net sales 11.7% (2.6) · Net profit EUR 2.3 million (0.3), growth 581.7% Key figures for the first half of 2016: · Net sales EUR 47.7 million (H1 2015: 42.7), growth 11.7% · Operating result EUR 4.7 million (2.1), growth 130.0% · Operating result of net sales 9.9% (4.8) · Net profit EUR 3.1 million (0.6), growth 397.4% The results do not include the Indian tax authorities decisions on tax refunds due to refund procedure being unfinished. Simultaneously Comptel specifies the outlook for 2016. Previous guidance was: “Comptel expects the 2016 net sales to continue to grow and operating profit to be in the range of 8–14% of revenue.” Specified guidance is: “Comptel expects the 2016 net sales to continue to grow and operating profit to be in the range of 9–14% of revenue.” The numbers presented are unaudited and preliminary numbers for the period. Comptel will publish its interim report for January-June on Tuesday 9th of August at 08.00. COMPTEL CORPORATION 15.7.2016 Board of Directors
Mr Juhani Hintikka, President and CEO, tel.+358 9 700 1131
Mr Tom Jansson, CFO, tel. +358 9 700 1131 Distribution: NASDAQ OMX Helsinki Major Media www.comptel.com About Comptel Corporation Life is digital moments. Comptel perfects these by transforming how you serve, meet and respond to the needs of Generation Cloud" customers. Our solutions allow you to innovate rich communications services instantly, master the orchestration of service and order flows, capture data-in-motion and refine it for your decision-making and actions. We connect digital demand and supply and apply intelligence to reduce complexity and friction in your business. Comptel has enabled the delivery of digital and communications services to more than 2 billion people. Every day, we care for more than 20% of all mobile usage data. Nearly 300 service providers across 90 countries have trusted us to perfect customers' digital moments and translate them to business moments. For more information, visit www.comptel.com."|
|body||The shareholders of Addtech AB (publ), reg. no. 556302-9726, are hereby given
notice to attend the Annual General Meeting to be held at 4:00 p.m. CET,
Wednesday, 31 August 2016, at IVA:s Konferenscenter, Grev Turegatan 16,
Stockholm. Registration for the meeting commences at 3:30 p.m. CET.
NOTICE OF PARTICIPATION
Shareholders who wish to attend in the proceedings of the Annual General Meeting
· be entered in the shareholders’ register kept on behalf of the company by
Euroclear Sweden AB, as of Thursday, 25 August 2016; and
· notify the Company’s head office at Addtech AB (publ), Box 5112, SE-102 43
Stockholm, Sweden or by telephone +46 (0)8-470 49 00, or by fax +46 (0)8-470 49
01, or via the Company’s website www.addtech.se/investors or via e-mail to
firstname.lastname@example.org no later than by 3:00 p.m., Thursday, 25 August 2016. The
notification must contain the shareholder’s name, social security number
(registration number), address, telephone number and the number of shares
represented as well as any attending counsel, maximum two.
Personal data obtained from the share register kept by Euroclear Sweden AB, the
notification and attendance at the meeting and information on representatives,
proxies and assistants will be used for registration, preparation of the voting
list for the Annual General Meeting and, if appropriate, the minutes of the
Shareholders whose shares are registered under a trustee must temporarily
register their shares in their own name in order to exercise their voting rights
at the Annual General Meeting. Such registration must be completed as of
Thursday, 25 August 2016, in order for due registration to take place.
If participation will be by proxy, the shareholder shall issue a written, signed
and dated proxy together with any documents verifying authority. Proxies for
legal entities must also be accompanied by a certificate of incorporation or
equivalent document verifying authority. A copy of the proxy and any certificate
of incorporation should, in advance, before the meeting be sent to the Company
at the above address. The original proxy shall also be presented at the meeting.
The Company provides the shareholders with proxy forms, which can be obtained at
the Company’s head office or on the Company’s website www.addtech.se/en latest
on 10 August 2016.
Opening of the Meeting.
Election of Chairman to preside over the Meeting.
Preparation and approval of Electoral Register.
Approval of the agenda.
Election of one or two persons to approve the Minutes.
Determination of whether the Meeting has been properly convened.
Presentation of the Annual report and the Audit Report and the Consolidated
Financial Statements and the Consolidated Audit Report.
Presentation by the CEO.
a. regarding adoption of the Income Statement and the Balance Sheet and the
Consolidated Income Statement and the Consolidated Balance Sheet,
b. regarding allocation of the Company’s profit in accordance with the duly
adopted Balance Sheet, and
c. regarding discharge from liability for the members of the Board of Directors
and the CEO.
Report on the work of the Nomination Committee.
Determination of the number of Board members.
Resolution of fees for the Board of Directors and the Auditor.
Election of Board members and Chairman of the Board of Directors.
Election of Auditor.
Resolution regarding guidelines for remuneration of members of senior
Resolution regarding issuing call options for repurchased shares and the
transfer of repurchased shares to management personnel (the “2016 Share-Related
Resolution regarding authorisation for the Board of Directors to decide on the
purchase and conveyance of own shares.
Closing of the Meeting.
THE NOMINATION COMMITEES PROPOSED RESOLUTION WITH RESPECT TO ITEMS 2 AND 11-14
ON THE AGENDA
It was resolved at the Annual General Meeting 2012 that the principles of
appointing the Nomination Committee shall be in force until further notice. In
accordance with these principles, the Chairman of the Board has contacted the
Company´s five largest directley registered shareholders in terms of votes as of
31 December, 2015 and asked them to appoint members together with the Chariman
to constitute the Nomination Committee for the Annual General Meeting 2016.
The Nomination Committee consists of Anders Börjesson (Chairman of the board),
Tom Hedelius, Åsa Nisell (appointed by Swedbank Robur fonder), Martin Wallin
(appointed by Lannebo fonder) and Johan Strandberg (appointed by SEB Investment
Management). Anders Börjesson is the Chairman of the Nomination Committe. The
Nomination Committee, whose members represent 50.3 percent of the votes in the
Company, has announced the following proposals:
2. Election of the Chairman to preside over the Meeting
The Chairman of the Board, Anders Börjesson, is proposed as Chairman to preside
over the Meeting.
11. Determination of the number of Board members
The Nomination Committee proposes that the Board of Directors shall consist of
seven Board members.
12. Determination of fees for the Board of Directors and the Auditor
The fee for each Board member shall be unchanged from the previous year. The
fees are as follows: SEK 500,000 to the Chairman of the Board, SEK 380,000 for
the Vice Chairman of the Board and SEK 250,000 to each of the other Board member
appointed by the Annual General Meeting who are not employed by the Company.
Total fees amount to SEK 1,880,000.
No fee is paid for committee work. Based upon individual agreement with Addtech
AB, a Board fee may be invoiced by a company or private business wholly owned by
the director. If this is done, the fee shall be increased by an amount
corresponding to the social security charges and value-added tax.
Audit fees will be paid according to approved invoice.
13. Election of Board members and Chairman of the Board of Directors
Re-election of the Board members Anders Börjesson, Eva Elmstedt, Tom Hedelius,
Ulf Mattsson, Malin Nordesjö and Johan Sjö. New election of Kenth Eriksson.
Anders Börjesson is proposed to be re-elected as Chairman of the Board.
Further information about the proposed directors is available on
14. Election of Auditor
The Nomination Committee proposes that the Annual General Meeting shall elect
the auditing company KPMG AB. KPMG AB has notified that the authorized auditor
George Pettersson will be appointed as Auditor in charge.
PROPOSAL BY THE BOARD OF DIRECTORS WITH RESPECT TO RESOLUTIONS UNDER ITEMS 9b
9b. Resolution with respect to disposition of the Company’s profit
according to the adopted Balance Sheet.
The Board of Directors proposes that the funds available for distribution are
allocated as follows: MSEK 218 (216) is distributed to shareholders and that the
remaining part of the Company´s earnings, MSEK 549 (689), is to be carried
This means that the Board of Directors proposes to the shareholders, that a
dividend of SEK 3.25 (3.25) per share and that Wednesday, 31 August 2016 shall
be the record date for the dividend.
If the Annual General Meeting approves the proposal, the dividend is calculated
to be distributed by Euroclear Sweden AB on Wednesday, 7 September 2016 to those
who on the record date are registered in the share register.
15. Resolution regarding guidelines for remuneration to members of
The Board of Directors proposes that the Annual General Meeting passes a
resolution on guidelines for remuneration to members of senior management with
the following principal terms:
The guidelines shall apply for remuneration to the CEO and the other members of
Addtechs’s Group management (the “Group Management”).
Addtech strives to offer total remuneration which is reasonable and competitive,
and which thereby serves to attract and retain qualified employees. The total
remuneration, which varies in relation to the individual´s and the Group´s
performance, may consist of the components set out below.
Fixed salary shall constitute the basis for the total remuneration. The salary
shall be competitive and reflect the responsibilities of the position. The fixed
salary shall be reviewed annually.
Variable salary is primarily based on the Group’s earnings growth, profitability
and cash flow. The annual variable portion may be for a maximum of 40 percent of
the fixed salary.
The Board of Directors will evaluate on an annual basis whether a long-term
incentive scheme shall be proposed to the Annual General Meeting or not, and if
so, whether the proposed long-term incentive scheme shall include transfer of
shares in the Company.
Retirement pension, health care benefits and medical benefits shall be designed
in such a way as to reflect rules, regulations and established practice on the
market. Pension plans shall be premium-based to the greatest extent possible.
Other benefits may be provided to individual members or the entire Group
Management and designed in relation to established practice on the market. These
benefits shall not constitute a significant portion of total remuneration.
Members of Group Management are obliged to comply with a 6-month period of
notice in the event of termination at the initiative of the employee and shall
have a right to a maximum of a 12-month period of notice in the event of
termination at the initiative of the Company. Upon termination by the Company,
members of the Group Management shall have the right to a severance payment
equivalent to a maximum of 12 months’ salary, in addition to salary and other
employment benefits during the period of notice. No severance payment shall be
payable in the event of termination at the initiative of the employee.
The Board of Directors shall have the right, in individual cases and where
special reasons exist to deviate from the above mentioned guidelines for
remuneration. In the event of any such deviation, information about this and the
reasons for the deviation shall be presented in the proposal regarding
guidelines for remuneration to members of senior management at the next Annual
The Remuneration Committee appointed by the Board of Directors prepares and
submits proposals to the Board of Directors regarding remuneration to the CEO.
Based on proposals by the CEO, the Remuneration Committee sets the remuneration
to the other members of the Group Management. The Board of Directors is informed
of the decisions of the Remuneration Committee.
The above guidelines are a full statement to the proposal for a decision at the
Annual General Meeting.
16. Resolution regarding issuing call options for repurchased shares
and the transfer of repurchased shares to management personnel (the “2016 Share
-Related Incentive Scheme”)
The Board of Directors proposes that the Annual General Meeting should pass a
resolution to adopt a long-term incentive scheme, the 2016 Share-Related
Incentive Scheme (the “Scheme”). The Scheme is proposed to include approximately
20 members of management personnel within the Addtech Group in which the
participants are being given the opportunity to acquire, at market price, call
options relating to class B shares in Addtech AB (publ) (the “Company”)
repurchased by the Company, with the participants receiving a certain subsidy on
premiums paid for the options after two years.
The proposal of the Board of Directors also means that the Annual General
Meeting approves that the Company transfer – with deviation from the
shareholders’ preferential rights – up to 300,000 of the Company’s repurchased
class B shares to the option holders at the agreed exercise price in connection
with any exercise of the call options (subject to any recalculations). The Board
of Directors’ proposal ultimately means that the Annual General Meeting approves
that the Series B shares that the Company acquired in accordance with previous
authorization are allowed to be transferred in order to secure delivery of
shares under the proposed Scheme. The company currently holds a total of
1,240,000 shares of series B in the Company.
This proposal has been prepared by the Company’s Remuneration Committee in
consultation with the Company’s Board of Directors. The decision to propose the
Scheme to the Annual General Meeting has been taken by the Board of Directors.
The Company’s directors are not covered by the Scheme.
The Scheme involves the following main terms and conditions:
a) The number of call options to be issued shall not exceed 300,000,
corresponding to approximately 0.4 percent of the total number of shares and
approximately 0.3 percent of the total number of votes in the Company (shares
class B held by the Company are included). Each call option entitles the holder
to acquire one (1) repurchased class B share in the Company during the period
from 16 September 2019 to 5 June 2020. Shares may not, however, be purchased
during any such period when trading in the Company’s shares is forbidden in
accordance with regulation (EU) no 596/2014 of the European Parliament and of
the Council of April 16 2014 on Market Abuse (or any other equivalent
legislation which applies at any given time).
b) The purchase price for shares upon exercise of the options shall
correspond to 120 percent of the volume-weighted average of the price paid for
the Company’s B shares on Nasdaq Stockholm during the period from 1 September
2016 to 14 September 2016.
c) The right to acquire call options shall be granted to the Group
Management and further approximately 15 members of management within the Addtech
Group who are directly able to influence the Group’s profits. The CEO shall be
offered a maximum of 37,500 call options, other members of the Group management
shall be offered a maximum of 30,000 call options per individual, and other
management personnel will be divided into two different categories, in which
individuals will be offered a maximum of 12,500 and a minimum of 7,500 call
d) If persons who are entitled to an allocation, refrain in full or in part
from acquiring call options offered to them, such un-acquired call options shall
be divided on a pro rata basis between those persons who are entitled to an
allocation and who have, in writing, expressed their interest in acquiring
additional call options. Persons who are entitled to an allocation may not come
to acquire more than an additional 30 percent of the original number of call
options offered in this manner.
e) The Board of Directors shall establish the final distribution of call
options according to the principles outlined in items c) and d) above, as well
as the number of call options the employees within each category shall be
offered to acquire.
f) Notice of acquiring call options must be given no later than 19
g) The premium for the call options shall correspond to the market value of
the call options according to an external independent valuation, applying the
Black - Scholes model. The measuring period for calculating the option premium
will be based on the volume-weighted average of the price paid for the shares of
class B in the Company on Nasdaq Stockholm during the period from 8 September
2016 until 14 September 2016.
h) Issuing call options to employees outside Sweden is dependent on tax
effects, that there is no legal impediment, and that the Board of Directors
determines that such allocation can be carried out with reasonable
administrative and financial resources. The Board of Directors shall be entitled
to make such minor amendments to the Scheme as required by applicable foreign
legislation and regulations.
i) The call options are freely transferable.
j) The number of shares which the call options bring entitlement to
acquire and the exercise price may be recalculated as a result of e.g. bonus
issues, share consolidations or splits, new issues, a reduction in the share
capital or similar actions. The time at which shares are transferred may be
brought forward as a result of any merger or similar actions.
k) In order to encourage participation in the Scheme, a subsidy can be paid
corresponding to the premium paid for each call option. This subsidy shall in
that case be paid during September 2018.
l) The company has the right to repurchase the call options by the holder
if the holder does not wish to use all acquired call options and has notified
the Company about this. Acquisition of options shall occur at a price which at
the time was equivalent to no more than the market value. Repurchase of call
options cannot be made during such period when trading with shares in the
Company is prohibited by Article 19 of the European Parliament and Council
Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (market abuse
regulation), or the prevailing corresponding legislation.
m) The Board of Directors shall, within the framework of the above conditions
and policies be responsible for the preparation and management of the Scheme.
The costs of the Scheme consist of the subsidy paid during September 2018 as
detailed above and the social security charges payable on this subsidy. The
total cost of the subsidy, including social security charges, has been estimated
to approximately MSEK 3.1 after corporation tax (calculated based on the
prevailing market conditions on 5 July 2016). Against this subsidy, the option
premium corresponds to a total of approximately MSEK 3.0 which the Company will
receive on transferring the call options (calculated based on the prevailing
market conditions on 5 July 2016), as a result of which the Scheme will not
involve any net charge to the Company’s equity.
The reason for deviation from the shareholders’ preferential rights and the
Board of Directors´s reasons for carrying out this Scheme is that senior
management within the Addtech Group should be able to benefit from and strive
for, through their own investment, an increase in the price of the Company’s
shares, thus more closely aligning the interests of senior managers and the
Company´s shareholders. The purpose of the Scheme is also to contribute towards
management personnel increasing their long term shareholdings in the Company.
The Scheme is also expected to create conditions for retaining and recruiting
competent personnel for the Addtech Group, to provide competitive remuneration
and to align the interests of the shareholders and management. The members of
management included in the Scheme are the group that, in an otherwise heavily
decentralized organization, can create positive effects through cooperation
between the Group’s subsidiaries. On the basis of this, the Board of Directors
believes that the introduction of the Scheme will have a positive effect on the
continued development of the Addtech Group, and that the Scheme will benefit
both the shareholders and the Company.
The Company has three long-term incentive schemes since earlier, the 2013, 2014
and 2015 Share Related Incentive Scheme.
In the Share-based Incentive Scheme of 2013, there are a total of 102,432
outstanding call options, which entitles the acquisition of 378,998 shares of
class B in the Company. The exercise price for these call options was set at SEK
85.90 per share and the exercise period covers the time from 19 September 2016
to 2 June 2017.
In the Share-based Incentive Scheme of 2014, there are a total of 350,000
outstanding call options, which entitles the acquisition of 430,500 shares of
class B in the Company. The exercise price for these call options was set at SEK
94.50 per share and the exercise period covers the time from 17 September 2017
to 1 June 2018.
In the Share-based Incentive Scheme of 2015, there are a total of 350,000
outstanding call options, which entitles the acquisition of 430,500 shares of
B in the Company. The exercise price for these call options was set at SEK
125.10 per share and the exercise period covers the time from 17 September 2018
to 3 June 2019.
All underlying 1,239,998 shares of class B in the Company of outstanding options
correspond in their entirety to the already repurchased class B shares in the
The resolution proposed by the Board of Directors in accordance with point 16
must be approved by shareholders representing not less than nine tenths of the
votes cast and shares represented at the Annual General Meeting.
17. Resolution to authorize the Board of Directors to decide on the
acquisition and transfer of own shares
The Board of Directors proposes that the Annual General Meeting passes a
resolution authorizing the Board of Directors to decide – during the period
until the next Annual General Meeting – to acquire a maximum number of class B
shares so that the Company’s holding of own shares at any given time does not
exceed 10 percent of the total number of shares outstanding in the Company.
Acquisition shall be made on Nasdaq Stockholm in accordance with stock exchange
regulations at a price within the, at each time, registered price interval,
which is the interval between the highest purchase price and the lowest sale
price. The acquisition will be paid in cash and must be made on one or several
The Board of Directors further proposes that the Annual General Meeting
authorizes the Board of Directors – during the period until the next Annual
General Meeting – to sell its own shares in ways other than on Nasdaq Stockholm.
The authorization may be exercised on one or more occasions and covers all
shares held by the Company at the time of the decision of the Board of
Directors. The authorization includes the right to decide to deviate from
shareholders’ preferential rights and that payment may be effected in forms
other than money.
The purpose of the authorization is to adapt the Group’s capital structure and
to enable companies or business operations to be acquired in the future through
payment with own shares. The holding of own shares also safeguards the Company's
obligations under the share-based incentive Scheme resolved at the Annual
General Meeting in 2013, 2014 and 2015 and the Share-Related Incentive Scheme
proposed under item 16 above.
The resolution proposed by the Board of Directors in accordance with point 17,
must be approved by shareholders representing not less than two thirds of the
votes cast and shares represented at the Annual General Meeting.
SHARES AND VOTES
The Company has issued a total of 68,198,496 shares, of these are 3,237,672
class A shares and 64,960,824 are class B shares, of which the Company holds
1,240,000 shares. The total number of votes, after deduction of the shares the
Company holds, is 96,097,544. This information relates to the situation at the
time of issuing this notice.
SHAREHOLDERS RIGHT TO REQUEST INFORMATION
Pursuant to Chapter 7, section 32 of the Swedish Companies Act (Sw.
aktiebolagslagen), the Board of Directors and the managing director are under a
duty to, if any shareholder so requests and the Board of Directors deems that it
can be made without material damage to the company, provide information at the
Annual General Meeting, regarding circumstances which may affect the assessment
of a matter on the agenda or the company’s economic situation. The duty of
disclosure also includes the Company’s relationship to other group companies,
the consolidated accounts and such circumstances regarding subsidiaries which
are set out in the preceding sentence.
Accounting documents, the auditor’s report and the Board of Directors’ complete
proposals in accordance with points 9b (including the Board of Directors’
statement in accordance with chapter 18, section 4 of the Swedish Companies
Act), 15 (including the auditor’s statement in accordance with Chapter 8,
section 54 of the Swedish Companies Act and the Nomination Committee’s
assessment of incentive schemes and application of the guidelines for
remuneration to senior management approved by the Annual General Meeting), 16
and 17 (including the Board of Directors’ statement in accordance with chapter
19, section 22 of the Swedish Companies Act) of the agenda will be available at
the Company no later than Wednesday, 10 August 2016 and will be sent to
shareholders who so request and provide their postal address. These documents
will also be available on the Company’s website on the same date. The Nomination
Committee’s proposals and reasoned opinions and details of all proposed members
of the Board of Directors will be available on the Company’s website from the
date of issuances of this notice.
Stockholm, July 2016
The Board of Directors
Addtech AB (publ)
Addtech AB, Box 5112, SE-102 43 Stockholm, Sweden
Phone +46 (0)8-470 49 00, Fax +46 (0)8-470 49 01, www.addtech.se,
Contact: Cory J. Boydston, Chief Financial Officer
Ashton Woods Homes
|body||Roswell, July 15, 2016 (GLOBE NEWSWIRE) -- ROSWELL, GEORGIA, July 15, 2016 - Ashton Woods USA L.LC. (the “Company”) announced today that the Company’s annual report for the year ended May 31, 2016 (the “Annual Report”) will be posted on the Company’s Intralinks site on or before Thursday, July 21, 2016. The Company will host a conference call on Thursday, July 21, 2016 at 11:00 AM EDT for the purpose of discussing the Annual Report and the Company’s operating results for the year ended May 31, 2016. Information necessary to access the call will be available on the Company’s Intralinks site. Holders or beneficial owners of, and prospective qualified investors in, the Company’s 6.875% Senior Notes Due 2021, securities analysts and market makers who wish to receive a copy of the Annual Report and information on how to access the conference call or who need access to the Intralinks site should contact Cory Boydston, the Company’s Chief Financial Officer, via email at email@example.com or by phone at (678) 597-2121.
ABOUT ASHTON WOODS: Ashton Woods is one of the nation’s largest private home building companies, blazing new trails in design and personalization to build homes as unique as the people who live in them. Collaborating with homeowners for over 25 years, the company and its team of world-renowned designers look beyond the conventional to draw inspiration from unexpected sources, resulting in exceptional design in every Ashton Woods home. Consistently recognized as one of the Most Trusted Builders in America by the Lifestory Research Most Trusted Builder in America StudySM, Ashton Woods’ collaborative approach is a key driver of its bestin-class customer satisfaction scores. For more information, or to experience the excitement of becoming another satisfied Ashton Woods homeowner, visit www.ashtonwoods.com.
Contact: Cory J. Boydston, Chief Financial Officer
Ashton Woods Homes
|body||The Board of Directors of JM decided to, during the third quarter, continue to
exercise the mandate for the buy-back of own shares that it received from the
Annual General Meeting on April 21, 2016.
The acquisition of ordinary shares in JM AB may only occur on NASDAQ Stockholm.
The authorization may be utilized on one or more occasions, although no longer
than up until the 2017 Annual General Meeting. The number of ordinary shares
that may be acquired is limited such that the Company's holdings do not at any
point in time exceed ten (10) percent of all the Company's shares. JM currently
holds a total of 2,745,279 own ordinary shares.
The acquisition of ordinary shares in JM AB may only occur at a price within the
NASDAQ Stockholm current spread, which refers to the spread between the highest
bid price and the lowest ask price.
The total amount of shares in JM is 75,238,439.
For additional information, please contact:
Claes Magnus Åkesson, CFO, +46 (0)8 782 89 71
This information is information that JM AB is obliged to make public pursuant to
the Financial Instruments Trading Act. The information was submitted for
publication at 13:30 CET on 2016-07-15.
JM is one of the leading developers of housing and residential areas in the
Nordic region. Operations focus on new production of homes in attractive
locations, with emphasis on expanding metropolitan areas and university towns in
Sweden, Norway and Finland. We are also involved in project development of
commercial premises and contract work, primarily in the Greater Stockholm area.
JM should promote long-term sustainability work in all of its operations. Annual
sales total approximately SEK 14 billion and the company has about 2,400
employees. JM is a public limited company listed on NASDAQ Stockholm, in the
Large Cap segment. More information is available at www.jm.se/en.|
|body||NEW YORK, July 15, 2016 (GLOBE NEWSWIRE) -- The Official Hip Hop Hall of Fame + Museum coming to NYC continues its expansion into Multi-Media Entertainment Productions and Digital Storytelling Archives by launching the Hip Hop Hall of Fame TV Channel and commissioning its first ever Documentary Film and Music Soundtrack for National and International Distribution Release. The HHHOF Entertainment Division has teamed up to produce the film with Hip Hop Icon Rob Base, who with partner DJ EZ Rock gave the world the hip-hop classic hit song ‘It Takes Two’, and who is a Harlem native that witnessed firsthand the rise of Hip Hop in Harlem.
Photos accompanying this announcement are available at
The “Mike & Dave: Harlem Hip Hop Story” brings to life the true story of Hip Hop Pioneers Mix Master Mike and Disco Dave, who formed one of the first independent hip hop record labels ever, preceding Def Jam founded by Russell Simmons & Rick Rubin, and who also were pioneers in the promotion of Old School Hip Hop Shows and Parties whose classic flyers are part of the Hip Hop Hall of Fame Museum’s Exhibit Collection, whose historic events included performances by many of the iconic founding groups of hip hop history including Grandmaster Flash & The Furious Five, Treacherous Three, The Crash Crew, The Cold Crush Brothers, Master Don & The Def Committee, Kool DJ AJ, and many more. The film will cover Harlem and NYC Hip Hop from the mid 1970s until the mid 1980s as hip hop exploded into the ‘Golden Era’, and Mix Master Mike & Disco Dave launched and produced many careers during this time period including The Boogie Boys with hit song ‘Fly Girl’, Doug E. Fresh, Biz Markie, and myself and more," stated Movie Co-Producer Rob Base, who also recently produced a Christian Comedy Theatrical Play entitled ‘UnEqually Yoked’ written by Ms. Lynette Blackwell for Rob-Lynn Productions that was well received by audiences around the country. This documentary story and film project is the brainchild of Kenny ‘DJ Lord Yoda X’ Syder, CEO of FreeDome7 Entertainment and a member of the Legendary Harlem Group The Crash Crew, a part of The Mike and Dave Records family. He is also Road Manager of Rob Base, Zulu Nation, and also serves as a Co-Chair of the HHHOF Artists Relations Committee. The production team has also added entertainment veteran producer and filmmaker Jimmy ‘Spice’ Curry, who has also worked as an executive and recorded with hip hop’s Iconic SugarHill Records in the late 1980s and who also produced the first Bahamian Movie ‘Filthy Rich G’s…’ in 1996. "This unique part of hip hop history will honor and celebrate how two brothers, Mike and Dave, from humble beginnings in the Lincoln Houses in Harlem, changed the game by Promoting Parties and forming their own Independent Record Label printing vinyl records and showing others how to make hip hop a business that is now worldwide," stated Co-Producer Kenny ‘DJ Lord Yoda X’ Syder. The HHHOF Team and Producers will begin filming this September and the movie & music soundtrack album is scheduled to be completed for Film Festivals and Release in 2017. The Film will also become part of The Hip Hop Hall of Fame Museum Collection for Archiving and Preservation of Hip Hop History. "This will be the first of many Hip Hop Movies & Documentaries, and Television Shows & Specials to be created and produced by Hip Hop Hall of Fame Entertainment and The Hip Hop Hall of Fame TV Channel launching this Fall," stated JT Thompson, Creator of The Hip Hop Hall of Fame Awards TV Show that aired on BET Cable Network in the 1990s, who serves as Founder & Chairman of The Hip Hop Hall of Fame + Museum & Entertainment Complex state of the art development project coming to NYC. For more information and participation contact Ben Davis at firstname.lastname@example.org or follow the Hip Hop Hall of Fame Museum website http://hiphophalloffame.org (In Beta Testing), and on Social Media Facebook http://facebook.com/hiphophalloffame, Twitter http://twitter.com/hiphophof,|
|id|| Instagram http://instagram.com/hiphophalloffametv and YouTube at http://YouTube.com/HipHopHallofFameTV. The photos are also available via AP PhotoExpress."|
Lori Ann Occhiogrosso
ZIOPHARM Oncology, Inc.
|body||BOSTON, July 15, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today issued the following statement regarding the Company's ongoing multicenter Phase 1 study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma (GBM) or grade III malignant glioma:
“This Phase I study is being conducted in late-stage, recurrent GBM, so these patients are all, unfortunately, medically fragile. The first two patient deaths, which occurred 6.7 months and 3.9 months after treatment, were unrelated to study drug. A third death has just been reported to us and we are collecting and analyzing information in order to properly and timely report it to the FDA. The cause of death is intracranial hemorrhage, which occurred some time after the patient had been discharged from the treating center. This is an isolated case, and there have been no reported related instances of brain hemorrhage in any pervious cohort or prior studies with Ad-RTS-hIL-12 + veledimex. Enrollment remains open in the study, and we will be discussing with our Safety Review Committee the appropriate course of action. For patients who have experienced multiple recurrences, as these patients have, prognoses are particularly poor. Median follow up in the first dose cohort from our study is now 8 months, in a population with an expected overall survival of 3 to 5 months for patients that have failed temozolomide and bevacizumab, or equivalent salvage chemotherapy. For the patients that remain in follow up in this Phase I study, we believe that preliminary overall survival remains encouraging. The Company expects to provide an update once a course of action has been determined.” About Glioblastoma Glioblastoma is an aggressive primary brain tumor affecting approximately 74,000 people worldwide each year.i, ii Recurrent glioblastoma is an aggressive cancer with one of the lowest 3-year survival rates, at 3%, among all cancers.iii For patients who have experienced multiple recurrences the prognosis is particularly poor, with a median overall survival (OS) of 6-7 months, while OS in patients that have failed temozolomide and bevacizumab, or equivalent salvage chemotherapy, is approximately 3-5 months.iv, v About ZIOPHARM Oncology, Inc.: ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer. The Company's immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies. Forward-Looking Safe-Harbor Statement: This press release contains certain forward-looking information about ZIOPHARM Oncology, Inc. that is intended to be covered by the safe harbor for forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding the progress, timing and results of preclinical and clinical trials involving the Company's drug candidates, and the progress of the Company's research and development programs. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied by, the forward-looking statements. These risks and uncertainties include, but are not limited to: whether chimeric antigen receptor T cell (CAR T) approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies, or any of our other therapeutic candidates will advance further in the pre-clinical or clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications|
| whether chimeric antigen receptor T cell (CAR T) approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies, and our other therapeutic products will be successfully marketed if approved|
| the strength and enforceability of our intellectual property rights|
| competition from other pharmaceutical and biotechnology companies|
| and the other risk factors contained in our periodic and interim SEC reports filed from time to time with the Securities and Exchange Commission, including but not limited to, our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, and our Quarterly Report for the quarter ended March 31, 2016. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events. Trademarks: RheoSwitch Therapeutic System® (RTS®) technology is a registered trademark of Intrexon Corporation. i. Mrugala MM. Advances and challenges in the treatment of glioblastoma: a clinician's perspective. Discov Med. 2013|
|15:221-230. http://www.discoverymedicine.com/Maciej-M-Mrugala/2013/04/25/advances-and-challenges-in-the-treatment-of-glioblastoma-a-clinicians-perspective/. Accessed March 24, 2015.|
|id|| ii. McCubrey JA, LaHair MM, Franklin RA. OSU—0312 in the treatment of glioblastoma. Mol Pharmacol. 2006|
|id|| iii. International Agency for Research on Cancer. World Cancer Report. 2003. http://www.iarc.fr/en/publications/pdfs-online/wcr/2003/WorldCancerReport.pdf.|
|id|| iv. Omuro, A. Glioblastoma and Other Malignant Gliomas. A Clinical Review JAMA. 2013 Nov 6|
|id|| v. Iwamoto et al. Patterns or relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009|
|url|| 73(15):1200-1206 |
|id||Lori Ann Occhiogrosso|
|id||ZIOPHARM Oncology, Inc.|
|contact_data||Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-|
|body||Dublin, July 15, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the Global Pet Grooming Market 2016-2020" report to their offering. |
|id|| The global pet grooming market to grow at a CAGR of 4.19% during the period 2016-2020. The global pet grooming market will grow at a steady pace during the forecast period, driven by increased pet ownership and awareness of the health benefits associated with owning a pet. |
|id|| A trend which is positively impacting the market is the increased demand for luxury pet services. Pet owners are increasingly buying premium products, and this stems from the fact that these days, owners treat their pets as part of their family, and want to provide them with the best. The concept of pet parents is also on the rise, where childless or single parents are adopting pets. With pet owners going for premium grooming products for their pets, market manufacturers are increasingly launching niche products to cater to the demand. The US is the leading country in the market. Baby boomers in the country, and in most other developed countries, have been seen to adopt pets as their children move away for education or get married. The growing number of baby boomers, therefore, bodes well for the market. |
|id|| According to the report, a key growth driver is the increase in pet related spending. Individuals have increased their pet ownership and pet spending worldwide. Global pet ownership increased from 53.6% to 56.5% between 2009 and 2013, with 66.8 million households owning pets. Pet owners are increasingly spending money and time on innovative and specialized premium pet grooming products, with most of them treating pets as part of their family. |
|id|| Further, the report states that one challenge that could curtail market growth is pet allergies among caregivers.|
|id|| Key vendors |
|id|| - Ancol Pet Products |
|id|| - Beaphar |
|id|| - Ferplast |
|id|| - Rolf C Hagen|
|id|| - Rosewood Pet Products|
|id|| - The Hartz Mountain|
|id|| Other prominent vendors |
|id|| - Bob Martin|
|id|| - BOSHEL|
|id|| - Chelsea Dogs|
|id|| - earthbath|
|id|| - Johnson's Veterinary Products|
|id|| - Just for Pets|
|id|| - Leonart F. Jollye|
|id|| - Mines for Pets|
|id|| - Oster|
|id|| - Pet Brands|
|id|| - Pettex|
|id|| - The Pet Warehouse |
|id|| Key Topics Covered: |
|id|| Part 01: Executive summary|
|id|| Part 02: Scope of the report|
|id|| Part 03: Market research methodology|
|id|| Part 04: Introduction|
|id|| Part 05: Market landscape|
|id|| Part 06: Market segmentation by product type|
|id|| Part 07: Geographical segmentation|
|id|| Part 08: Key leading countries|